The impact of biologic response modifiers on hepatitis B virus infection

Bibliography

• Lok ASF. Chronic hepatitis B. N Engl J Med 2002;346:1682-3
   PubMed Web of Science ®Google Scholar
• Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500
   PubMed Web of Science ®Google Scholar
• Shi YH, Shi CH. Molecular characteristics and stages of chronic hepatitis B virus infection. World J Gastroenterol 2009;15:3099-105
   PubMed Web of Science ®Google Scholar
• EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42
   PubMed Web of Science ®Google Scholar
• Ribeiro CSS, Visentainer JEL, Moliterno RA. Association of cytokine genetic polymorphisms with hepatitis B infection evolution in adult patients. Mem Inst Oswaldo Cruz 2007;102:435-40
   PubMedGoogle Scholar
• Hosel M, Quasdorff M, Wiegmann K, Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009;50:1773-82
   PubMed Web of Science ®Google Scholar
• Larrubia JR, Benito-Martinez S, Miquel-Plaza J, Cytokines – their pathogenic and therapeutic role in chronic viral hepatitis. Rev Esp Enferm Dig 2009;101:343-51
   PubMed Web of Science ®Google Scholar
• Ganem D, Prince AF. Hepatitis B virus infection – natural history and clinical consequences. N Engl J Med 2004;350:1118-29
   PubMed Web of Science ®Google Scholar
• Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16
   PubMed Web of Science ®Google Scholar
• Rasheed Z, Haqqi TM. Update on targets of biologic therapies for rheumatoid arthritis. Curr Rheumatol Rev 2008;4:246-60
   PubMedGoogle Scholar
• Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Int Care Med 2004;19:320-34
   PubMedGoogle Scholar
• Nurmohamed MT. Newer biological agents in the treatment of rheumatoid arthritis. Drugs 2009;69:2035-43
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Iqbal I, Stern RL. Considerations with the use of biological therapy in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 2004;3:391-403
   PubMedGoogle Scholar
• Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39:327-46
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79
   PubMed Web of Science ®Google Scholar
• Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25(Suppl 46):S46-56
   PubMedGoogle Scholar
• Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010;29:1021-9
   PubMed Web of Science ®Google Scholar
• Weaver AL. Differentiating the new rheumatoid arthritis biologic therapies. J Clin Rheumatol 2003;9:99-114
   PubMed Web of Science ®Google Scholar
• Case JP. Old and new drugs used in rheumatoid arthritis: part 2. Am J Therapeutics 2001;8:163-79
   PubMedGoogle Scholar
• Penn H. Biologic therapies in autoimmune diseases. Clin Med 2006;6:105-8
   PubMed Web of Science ®Google Scholar
• Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 1994;179:841-8
   PubMed Web of Science ®Google Scholar
• Roux CH, Brocq O, Breuil V, Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondyloarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006;45:1294-7
   PubMed Web of Science ®Google Scholar
• Hohler T, Kruger A, Gerken G, A tumour necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998;111:579-82
   PubMed Web of Science ®Google Scholar
• Wilson AG, Symons JA, McDowell TL, Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-9
   PubMed Web of Science ®Google Scholar
• Ben-Ari Z, Mor E, Papo O, Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003;98:144-50
   PubMed Web of Science ®Google Scholar
• Li HQ, Li Z, Liu Y, Association of –238G/A and –857C/T polymorphisms of tumor necrosis factor-alpha gene promoter region with outcomes of hepatitis B virus infection. Biomed Environ Sci 2006;19:133-6
   PubMed Web of Science ®Google Scholar
• Li HQ, Li Z, Liu Y, Association of polymorphism of tumor necrosis factor-alpha gene promoter region with outcome of hepatitis B virus infection. World J Gastroenterol 2005;11:5213-17
   PubMed Web of Science ®Google Scholar
• Kim YJ, Lee HS, Yoon JH, Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003;12:2541-6
   PubMed Web of Science ®Google Scholar
• Cheong JY, Cho SW, Hwang IL, Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. J Gastro Hepatology 2006;21:1163-9
   PubMed Web of Science ®Google Scholar
• Niro GA, Fontana R, Gioffreda D, Tumor necrosis factor gene polymorphisms and clearance or progression of hepatitis B virus infection. Liver Int 2005;25:1175-81
   PubMed Web of Science ®Google Scholar
• Du T, Guo XH, Zhu XL, Association of TNF-alpha promoter polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population. J Viral Hepat 2006;13:618-24
   PubMed Web of Science ®Google Scholar
• Fang JWS, Shen WW, Meager A, Activations of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection. Am J Gastroenterol 1996;91:748-53
   PubMed Web of Science ®Google Scholar
• Rehermann B. Intrahepatic T-cells in hepatitis B: viral control versus liver cell injury. J Exp Med 2000;191:1263-8
   PubMed Web of Science ®Google Scholar
• Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci USA 1997;94:8744-9
   PubMed Web of Science ®Google Scholar
• Lau GK, Yiu HH, Fong DY, Early is superior to deferred pre-emptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-9
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Zein NN, Vassilopoulos D. Hepatits B virus reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65:983-9
   PubMed Web of Science ®Google Scholar
• Saag K, Teng GG, Patkar NM, American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84
   PubMed Web of Science ®Google Scholar
• Ferri C, Govoni M, Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Curr Opin Rheumatol 2010;22:443-50
   PubMed Web of Science ®Google Scholar
• Raftery G, Griffiths B, Kay L, Chronic viral hepatitis and TNF-alpha blockade. Rheumatology 2007;46:1381
   PubMed Web of Science ®Google Scholar
• Montiel PM, Solis JA, Chirinos JA, Hepatitis B virus reactivation during therapy with etanercept in an HBsAg negative and anti-HBs-positive patient. Liver Int 2008;28:718-20
   PubMed Web of Science ®Google Scholar
• Madonia S, Orlando A, Scimeca D, Occult hepatitis B and infliximab-induced HBV reactivation [letter]. Inflamm Bowel Dis 2007;13:508-9
   PubMed Web of Science ®Google Scholar
• Kim YJ, Bae SC, Sung YK, Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 2010;37:346-50
   PubMed Web of Science ®Google Scholar
• Caporali R, Bobbio-Pallavicini F, Atzeni F, Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res 2010;62:749-54
   PubMed Web of Science ®Google Scholar
• Charpin C, Guis S, Colson P, Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009;11:179-84
   PubMed Web of Science ®Google Scholar
• Zhang P-A, Li Y, Xu P, Polymorphisms of interleukin-1B and interleukin-1 receptor antagonist genes in patients with chronic hepatitis B. World J Gastroenterol 2004;10:1826-9
   PubMed Web of Science ®Google Scholar
• Ranjbar M, Alizadeh AHM, Hajilooi M, Polymorphisms of interleukin-1R receptor antagonist genes in patients with chronic hepatitis B in Iran. World J Gastroenterol 2006;12:5044-7
   PubMed Web of Science ®Google Scholar
• den Broeder AA, de Jong E, Franssen MJAM, Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 2006;65:760-2
   PubMed Web of Science ®Google Scholar
• Kineret. Washington DC: Drugs@FDA. 2004. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [Last accessed 13 January 2011]
   Google Scholar
• Carroll, Matthew B ([email protected]). ‘Anakinra and HBV.’ Email to Pilstrom Bjorn of Biovitrium ([email protected]) 5 Aug 2010
   Google Scholar
• Heinrich PC, Behrmann I, Muller-Newen G, Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334:297-314
   PubMed Web of Science ®Google Scholar
• Hushaw LL, Sawaqed R, Sweis G, Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag 2010;6:143-52
   PubMed Web of Science ®Google Scholar
• Ataseven H, Bahcecioglu IH, Kuzu N, The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediators Inflamm 2006;2006(4):78380
   PubMedGoogle Scholar
• Liu Q, Feng GX, Lin YL, Detection of interleukin-6 and -12 in of hepatitis B patients and its clinical significance. Di Yi Jun Yi Da Xue Xue Bao 2001;21:858-9
   PubMedGoogle Scholar
• Kuo TM, Hu C, Chen YL, HBV replication is significantly reduced by IL-6. J Biomed Sci 2009;16:41-9
   PubMed Web of Science ®Google Scholar
• Wong VW, Yu J, Cheng AS, High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009;124:2766-70
   PubMed Web of Science ®Google Scholar
• Li C, Zhi-Xin C, Li-Juan Z, The association between cytokine gene polymorphisms and the outcomes of chronic HBV infection. Hepatol Res 2006;36:158-66
   PubMed Web of Science ®Google Scholar
• Park BL, Lee HS, Kim YJ, Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med 2003;35:76-82
   PubMed Web of Science ®Google Scholar
• Fabris C, Toniutto P, Bitetto D, Gene polymorphism at the interleukin 6 –174 G>C locus affects the outcome of chronic hepatitis B. J Infection 2009;59:144-5
   PubMed Web of Science ®Google Scholar
• Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology 2008;47:1838-40
   PubMed Web of Science ®Google Scholar
• Kishida D, Okuda Y, Onishi M, Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol 2011: published onlone 8 October 2010. doi: 10.1007/s10165-010-0365-8
   Google Scholar
• Koike R, Harigai M, Atsumi T, Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 2009;19:351-7
   PubMed Web of Science ®Google Scholar
• Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B-cells. Seminars in Hematology 2010;47:170-9
   PubMed Web of Science ®Google Scholar
• Lazdina U, Cao T, Steinbergs J, Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B-cells. J Virol 2001;75:6367-74
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Yamamoto Y, Tanaka J, Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy 2009;1:1053-61
   PubMed Web of Science ®Google Scholar
• Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 2010;149:3-13
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Kanamori H, Mori A, Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005;4:599-608
   PubMedGoogle Scholar
• Pyrpasopoulou A, Douma S, Vassiliadis T, Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 2009: published on line 13 September 2009, doi: 10.1007/s00296-009-1202-2
   Google Scholar
• Rodriguez-Escalera C, Fernandez-Nebro A. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology 2008;47:1732-3
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Abbas AK. T-Cell costimulation – biology, therapeutic potential, and challenges. N Engl J Med 2006;355:973-5
   PubMed Web of Science ®Google Scholar
• Thio CL, Mosbruger TL, Kaslow RA, Cytotoxic T-lymphocyte antigen 4 gene and recover from hepatitis B virus infection. J Virol 2004;78:11258-62
   PubMed Web of Science ®Google Scholar
• Alizadeh AHM, Hajilooi M, Ranjbar M, Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to chronic hepatitis B. World J Gastroenterol 2006;12:630-5
   PubMed Web of Science ®Google Scholar
• Gu X, Qi P, Zhou F, +49G>A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 2010;71:83-7
   PubMed Web of Science ®Google Scholar
• Levine, Loree. “Information you requested from Bristol-Myer-Squibb.” Message to Matthew B. Carroll. 12 August 2010. E-mail.
   Google Scholar
• Pham T, Claudepierre P, Constantin A, Abatacept therapy and safety management. Joint Bone Spine 2009;76(Suppl 1):S1-56
   PubMedGoogle Scholar
• Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006;21:1366-71
   PubMed Web of Science ®Google Scholar
• Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39
   PubMed Web of Science ®Google Scholar